Skip to content
Screener

Perspective Therapeutics CATX Q2 2026 earnings

Reported August 10, 2026 · After market close

Revenue$81.0KMiss by $9.5K
EPS-$0.22Beat by $0.03
Revenue estimate$90.5K
EPS estimate-$0.25

Next report

Nov 9, 2026 (in 2 months)
Revenue estimate$62.1K
EPS estimate-$0.24

Financials

Q2 2026

Income statement

See full
Operating income-$29.3M-21.7%
Net income-$26.8M-24.7%
EPS (diluted)-$0.22+24.1%

Balance sheet

See full
Cash & equivalents$48.5M+68.1%
Total debt$3.9M+11.1%
Total equity$323.9M+21.9%
Total assets$392.0M+26.2%

Cash flow

See full
Operating cash flow-$20.7M-3.5%
CapEx$14.2M+1,284%
Free cash flow-$34.8M-66.1%

Valuation & ratios

Valuation

as of 09/17/26
See full
Market cap$308.21M+36.5%
Enterprise value$263.63M+31.5%

Returns & leverage

See full
Return on equity-39.5%+14.0pp
Debt / equity0×0.0×
Current ratio6.6×-8.5×

FAQ

When did Perspective Therapeutics report Q2 2026 earnings?
Perspective Therapeutics (CATX) reported Q2 2026 earnings on August 10, 2026 after market close.
What were Perspective Therapeutics's Q2 2026 revenue and EPS?
Perspective Therapeutics reported revenue of $81.0K and eps of $-0.22 for Q2 2026.
Did Perspective Therapeutics beat estimates in Q2 2026?
Revenue missed the consensus estimate of $90.5K by $9.5K. EPS beat the consensus estimate of $-0.25 by $0.03.
How did Perspective Therapeutics's Q2 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 65.4% from $234.0K a year earlier and eps grew 26.7% from $-0.30.
Where can I find Perspective Therapeutics's Q2 2026 SEC filings?
You can read the 8-K earnings release (0001193125-26-342495) and the 10-Q periodic report (0001193125-26-342512) directly on SEC EDGAR. The filing index links above go to sec.gov.